This article has Open Peer Review reports available.
Development of an invasively monitored porcine model of acetaminophen-induced acute liver failure
© Newsome et al; licensee BioMed Central Ltd. 2010
Received: 5 January 2010
Accepted: 30 March 2010
Published: 30 March 2010
The development of effective therapies for acute liver failure (ALF) is limited by our knowledge of the pathophysiology of this condition, and the lack of suitable large animal models of acetaminophen toxicity. Our aim was to develop a reproducible invasively-monitored porcine model of acetaminophen-induced ALF.
35kg pigs were maintained under general anaesthesia and invasively monitored. Control pigs received a saline infusion, whereas ALF pigs received acetaminophen intravenously for 12 hours to maintain blood concentrations between 200-300 mg/l. Animals surviving 28 hours were euthanased.
Cytochrome p450 levels in phenobarbital pre-treated animals were significantly higher than non pre-treated animals (300 vs 100 pmol/mg protein). Control pigs (n = 4) survived 28-hour anaesthesia without incident. Of nine pigs that received acetaminophen, four survived 20 hours and two survived 28 hours. Injured animals developed hypotension (mean arterial pressure; 40.8 +/- 5.9 vs 59 +/- 2.0 mmHg), increased cardiac output (7.26 +/- 1.86 vs 3.30 +/- 0.40 l/min) and decreased systemic vascular resistance (8.48 +/- 2.75 vs 16.2 +/- 1.76 mPa/s/m3). Dyspnoea developed as liver injury progressed and the increased pulmonary vascular resistance (636 +/- 95 vs 301 +/- 26.9 mPa/s/m3) observed may reflect the development of respiratory distress syndrome.
Liver damage was confirmed by deterioration in pH (7.23 +/- 0.05 vs 7.45 +/- 0.02) and prothrombin time (36 +/- 2 vs 8.9 +/- 0.3 seconds) compared with controls. Factor V and VII levels were reduced to 9.3 and 15.5% of starting values in injured animals. A marked increase in serum AST (471.5 +/- 210 vs 42 +/- 8.14) coincided with a marked reduction in serum albumin (11.5 +/- 1.71 vs 25 +/- 1 g/dL) in injured animals. Animals displayed evidence of renal impairment; mean creatinine levels 280.2 +/- 36.5 vs 131.6 +/- 9.33 μmol/l. Liver histology revealed evidence of severe centrilobular necrosis with coagulative necrosis. Marked renal tubular necrosis was also seen. Methaemoglobin levels did not rise >5%. Intracranial hypertension was not seen (ICP monitoring), but there was biochemical evidence of encephalopathy by the reduction of Fischer's ratio from 5.6 +/- 1.1 to 0.45 +/- 0.06.
We have developed a reproducible large animal model of acetaminophen-induced liver failure, which allows in-depth investigation of the pathophysiological basis of this condition. Furthermore, this represents an important large animal model for testing artificial liver support systems.
Acute liver failure (ALF) is a dramatic clinical syndrome that results from massive hepatic necrosis. The mortality of ALF remains high despite progress in the fields of intensive care management and liver transplantation . ALF refers to the rapid development of severe acute liver injury with impaired synthetic function and encephalopathy in subjects with previously normal, or well-compensated liver disease . Generation of a suitable animal model would allow for a greater understanding of the underlying pathophysiology of this condition and stimulate the development and refinement of treatments for ALF. There is a need for a suitable large animal model of hepatic injury to facilitate the development of bio-artificial liver support systems in humans and to assist pre-clinical assessment .
Since the recognition of acetaminophen-induced ALF in the 1960s, acetaminophen overdose has become the commonest cause of liver failure in the United Kingdom . Although an effective antidote (N-acetylcysteine) has been available for many years, the late presentation of many cases ensures a significant number develop liver failure. Early large animal models of acetaminophen toxicity were unreliable, producing inconsistent toxicity from animal to animal. Gazzard et al  showed that dogs receiving oral doses greater than 1 g/kg died of nonhepatic causes, becoming cyanotic immediately before death with methylene blue-resistant methaemoglobinaemia. Human studies have shown that serum acetaminophen levels must be >140 mg/mL for greater than 20 hours for consistent hepatic necrosis to occur . Using this, Francavilla et al  studied various doses and dosing schedules on 52 beagle dogs. These initially received 750 mg/kg acetaminophen subcutaneously followed by 200 mg/kg nine hours later, and then a further 200 mg/kg twenty-four hours later. Mortality rates in this group were: 0% at 24 hours, 10% at 48 hours, and 90% at 72 hours. Serum transaminase levels were greatly increased to 8206 +/- 3000 U/L at 48 hours and 21 253 +/- 3746 U/L at 72 hours. This correlated with liver biopsy samples that revealed severe centrilobular necrosis.
Several approaches have been adopted to control methaemoglobinaemia in animal models: Kelly et al  using dogs, suspected high plasma acetaminophen levels were responsible for the lethal methaemoglobinaemia that characterised their early experiments. They controlled acetaminophen infusion in an attempt to maintain its levels at 175 to 200 mg/mL for the first 20 hours. Methylene blue was administered at 10 mg/kg if blood samples appeared brown on visual inspection. Pilot data showed that levels of acetaminophen greater than 300 mg/mL were associated with severe methemoglobinemia.
Cellular glutathione (GSH) levels must be depleted to approximately 20% of their original levels before toxic acetaminophen damage can occur, [9, 10]. To reduce variation in the acetaminophen dose required and the time taken for the development of signs, Kelly et al  attempted to deplete GSH levels by administering 2 mmol/kg of buthionine sulfoximine (BSO) 2 hours before acetaminophen. BSO , an analogue for glutathione synthetase, binds and irreversibly inactivates this enzyme which is the final enzyme in GSH synthesis. The rapid turnover of cellular GSH, ensures that enzyme inactivation leads to a rapid reduction in the hepatocyte GSH concentrations. Kelly et al  showed that BSO administration to mice decreased hepatic GSH stores to 15% to 20% of normal within 2 hours. They showed greater liver damage in the BSO group in terms of alanine aminotransferase activity, prothrombin time, bilirubin level, and histological characteristics. Miller et al  administered phenobarbital to induce cytochrome P-450 enzymes and thus potentiate subsequent acetaminophen toxicity. This increased liver damage and decreased animal survival.
There has been limited success in the development of suitable large animal models of acetaminophen induced liver injury. In the study described here we used bed-side biochemical and invasive haemodynamic monitoring during acetaminophen-induced liver damage in a reproducible and controlled manner. Using this approach we markedly reduced previously reported problems, i.e., methaemoglobinaemia and cardiovascular collapse, and produced a large animal model which reliably reproduces the syndrome of ALF observed in clinical practice.
Animal experiments were performed in accordance with the Home Office regulations under the Animal (Scientific Procedures) Act 1986 as per Project licence 60/2389.
All animals received humane care and study protocols complied with our institution's guidelines.
13 Large White pigs (median body mass 35 kg) were maintained under. Anaesthesia was induced with Ketamine and Midazolam, and subsequently maintained with isoflurane and nitrous oxide according to tidal volume. Background hydration was maintained at a rate of 2 mls/kg/hr using a combination of 0.9% Normal Saline and 5% Dextrose according to electrolyte results from arterial blood gas sampling and urine output. Boluses of colloid (Gelofusine) were administered for episodes of hypotension. Heater pads were used to ensure that core (rectal) temperature was maintained between 37-39°C (the normal temperature range for pigs) . Haemodynamic variables were monitored continuously using a Datex AS/3 monitoring system (Datex Ohmeda, Stirling, UK) and recorded at one minute intervals using the Datex Collect programme on a laptop computer. Measurements were made from arterial, central venous and pulmonary arterial cannulae. The latter allowed hourly left atrial pressure (from pulmonary capillary wedge pressure) and cardiac output (thermodilution) measurements: 10 mls isotonic saline aliquots at 4°C were injected through the injectate port of the pulmonary artery catheter using a closed injectate system (CO-Set plus, Baxter Edwards Critical Care, Irvine, CA, USA). Three measurements were made at random points during the respiratory cycle and an average value taken for each measurement. Intracranial pressure (ICP) was monitored with a subdural pressure transducer (Camino 110-4B, Integra Lifesciences Corp, New Jersey, USA). Correct positioning was confirmed by obtaining an appropriate waveform that fluctuated with ventilation. Urine output was monitored via a urethrostomy. Microbiological testing was performed routinely for all animals.
All animals were pre-treated with phenobarbital 20 ml orally per day for 5 days prior to each experiment to induce cytochrome p450 enzymes (n = 13 pigs). Total cytochrome p450 levels were measured using CO difference spectroscopy of sodium hydrosulphite samples . In nine animals intravenous acetaminophen was administered while four animals were used as controls and monitored invasively but did not receive any acetaminophen infusions. An initial loading dose of acetaminophen was administered by intravenous infusion (0.1875 g/kg) followed by an infusion for 12 hours (1.8 mg/kg/min) with the intention of keeping blood acetaminophen concentration between 200-300 mg/l (n = 9 pigs). Acetaminophen levels were monitored by bed-side testing using the Acetasite system (Indiana, USA). Arterial blood gas and lactate levels were measured using a Hewlett Packard I-Stat point-of-care blood analysis system. Methaemoglobin was concurrently measured spectrophotometrically as previously described .
Experiments lasted up to 28 hours, and any animals surviving at this time-point were euthanased. Necropsy samples of liver, kidney and brain were then taken. Samples were fixed in formalin and embedded in paraffin. Sections were cut at 5 microns and haematoxylin & eosin stained for routine histological analysis.
Standard laboratory assays were used for the measurement of liver and renal function, full blood count and coagulation parameters (prothrombin time, factors V, VII, VIII). Serum aspartate aminotransferase, albumin, potassium and creatinine analysis were measured on an Olympus AU2700 automated analyser (Olympus UK Ltd, Watford, UK.) using proprietary diagnostic kits.
NMR spectroscopy was used to measure a number of amino acids in serum to calculate Fischer's ratio , which is the ratio of the aromatic amino acids (tyrosine and phenylalanine) to branch chain amino acids (leucine, isoleucine and valine). Reversal of Fischer's ratio is a reliable marker of development of encephalopathy in an anaesthetised model. Samples for NMR spectroscopy were prepared and analysed as described previously .
Results are presented as means ± S.E.M, as analysis demonstrated the data to be normally distributed. Significance of the differences between means was assessed using the two-sided t test. Two-sided t test was performed to determine the statistical difference after 24 hours between the two groups. Values of p < 0.05 were considered significant.
Cytochrome p450 levels measured in homogenised liver tissue from phenobarbital pre-treated animals (n = 3 pigs)were significantly higher than in animals which had not received phenobarbital (300 +/- 86 vs 100 +/- 31, p = 0.01) pmol/mg protein. All animals in this study subsequently received phenobarbital
Acetaminophen toxicity and methaemoglobinaemia
Cardio respiratory evaluation
Evidence of encephalopathy: Fischer's ratio
Intracranial pressure (ICP) measurements
Intracranial pressure did not alter in any of the control or injured animals at any time during the experiment. Mean levels were 8 mmHg. Cerebral perfusion pressure was less in injured animals, principally because of arterial hypotension; this was not associated with obvious cerebral histopathology.
Discussion and Conclusions
The major role for an ALF model is to provide a more controlled experimental environment than currently exists . An ideal model should satisfy the following criteria: 1) induced hepatic failure should be reversible; 2) the features of liver damage should be reproducible; 3) selective damage should lead to fatal liver failure over a period similar to that encountered in the human condition; but 4) with sufficient time to allow the option for successful treatment; 5) the model should be large enough to accommodate anthropocentric therapies; and 6) the toxins used should not be hazardous to laboratory personnel. A pig model would be preferable as it has the potential to fulfil all of these criteria, and also importantly shares very similar liver metabolic function with human liver .
The porcine model described here develops most of the signs typifying acute liver injury/failure, namely: tachycardia, hypotension, increased cardiac output, decreased systemic vascular resistance, coagulopathy, renal failure and altered hepatic biochemistry. Consequently, it is the only animal model of acetaminophen-induced liver injury large enough to allow monitoring at a level equivalent to intensive care. Whilst the outcome of acetaminophen-injured pigs is relatively reproducible there still remain some inherent variations highlighting the difficulty of such studies. This reinforces the need to perform large studies when using such animals to ensure that individual variations can be accounted for.
Our model showed the typical increase in cardiac output and reciprocal reductions in SVR found in the clinical setting. Of note this is accelerated within the porcine model, starting within 16 hours of the onset of liver damage. This is likely a reflection of pre-treatment with phenobarbitone. The increased PVR in the context of normal PaO2 values was in keeping with the increased requirement for positive end-expiration pressure (PEEP) during ventilation. This may have indicated the onset of an ARDS-like picture, although lung histology would be important to support this conclusion. That PAOP did not increase suggests that the ventilatory changes were not associated with pulmonary oedema secondary to left ventricular failure. A non-significant reduction in PVR Index after liver injury has been described . The reason for this difference is unclear. Acute lung injury is common in patients with acetaminophen-induced fulminant hepatic failure and is associated with systemic circulatory failure, cerebral oedema and high mortality.
The marked reduction in Factor V and VII levels in the current model were consistent with severe liver injury. The Clichy criteria  deemed a reduction of Factor V levels to <20-30% as the trigger for liver transplantation; this was the case in most animals in this experiment. The absence of changes in Factor VIII levels indicate DIC was not the cause of altered levels of other coagulation factors.
An increase in AST levels indicated the development of liver necrosis, although these were not as high as are seen in patients. Similarly, a rise in bilirubin did not occur. This may reflect a species-specificity of the assay used, or insufficient time for bilirubin to rise. It is possible that there are subtle variations in this model compared to humans in that some systemic features prevail over a liver focused pattern of injury. Liver tissue analysis revealed severe coagulative necrosis in some animals with moderate and mild injury in others. This supports the probability that significant liver injury accounts for the clinical syndrome reported here. Although there is some variability in the liver injury seen in this model, there is still significant liver injury in the majority of animals. Indeed, this variation closely mimics what is seen clinically.
There are several explanations for the failure to observe changes in ICP. The time course may have been too brief. However, a raised ICP is not always encountered in the clinical setting, or only in association with other factors such as sepsis. It may also reflect differences in the pathophysiology of drug-induced ALF as opposed to ischaemic models of ALF. Measurements of arterial ammonia, cerebral blood flow or the use of cerebral microdialysis may help to clarify intracranial effects in future studies. Biochemical analysis suggested that animals may have been developing encephalopathy, although in the absence of ICP changes and with general anaesthesia it is difficult to be certain. Fischer's ratio , the ratio of the aromatic amino acid (AAA; tyrosine and phenylalanine) to branch chain amino acid (BCAA; leucine, isoleucine and valine) concentrations has a value of 3 to 4 in clinical liver failure but when this ratio is reversed and is in absolute figures <1.4 then most patients develop hepatic encephalopathy.
There was evidence of marked renal impairment, although fatal hyperkalaemia was not observed. Renal dysfunction is an important feature of acetaminophen induced liver failure , and the renal histology in treated animals was consistent with a toxic injury rather than the distinctive pattern of frank outer medullary tubular necrosis encountered with ischaemia, i.e., critical hypotension.
This study demonstrates the importance of continuous monitoring of acetaminophen levels, the one animal from which it was withheld died from methaemoglobinaemia. The amount of acetaminophen required to maintain levels between 200-300 mg/l for 12 hours was calculated beforehand, but it was necessary in every case to reduce the infusion rate (and the total dose administered) as acetaminophen levels exceeded this range. Levels greater than 250 mg/l increased serum methaemoglobin levels, although this usually resolved by stopping the acetaminophen infusion which allowed plasma levels to fall. Acetaminophen and its intermediates oxidise haemoglobin to methaemoglobin, which is unable to carry oxygen. Although it occurs in human beings, it is less marked than in cats, dogs, and pigs. In some species, methemoglobin is reduced to hemoglobin by the methemoglobin reductase using reduced glutathione (GHS) as a substrate. GSH itself is recycled by the glutathione reductase, using reduced nicotinamide-adenine dinucleotide phosphate (NADPH) from the pentose phosphate pathway. Due to the glucose impermeability of porcine red blood cells (compared with rats and rabbits) there is a diminution in generation of NADPH and hence decreased reduction of methaemoglobin . Levels of methaemoglobinaemia in pigs  administered acetaminophen are only one-half those reported in cats  and dogs . There are several measures to control methaemoglobin levels in animal models. Kelly et al  suspected high plasma acetaminophen levels were responsible for lethal methaemoglobinaemia and so tried to prevent them. Not having access to bedside testing and thus being unable to prevent high acetaminophen levels they administered MB at 10 mg/kg if the blood appeared brown on visual inspection. The usefulness of this strategy was not confirmed in the current study.
Methylene blue is the recognized clinical treatment for methaemoglobinaemia and acts by reducing methaemoglobin back to haemoglobin. Its action depends on the availability of adequate NADPH concentrations within the erythrocyte; a deficiency of NADPH availability leads to further methaemoglobinaemia. On the single occasion it was used in the current study the animal died of cardiovascular collapse 5 minutes later.
Presence of anaemia
Miller et al  found that the haematocrit fell rapidly (25% decrease from the initial packed cell volume) in sixty percent of animals 1 to 2 hours before death. The cause of anaemia in their study was unclear, and may reflect extravascular haemolysis within the spleen. The haemoglobin nor haematocrit levels did not fall in either the control nor the treatment groups in the current study.
In summary, we have described the first intensively monitored porcine model of acetaminophen-induced severe liver injury which displays most of the features seen in the human condition. This large animal model can play an important role in the evaluation of the effectiveness of liver support systems, as well as providing us with the ability to develop a much better understanding of the pathophysiology of this devastating clinical syndrome.
This work was funded by the Chief Scientist's Office.
- Plevris JN, Schina M, Hayes PC: Review article: the management of acute liver failure. Aliment Pharmacol Ther. 1998, 12 (5): 405-418. 10.1046/j.1365-2036.1998.00320.x.View ArticlePubMedGoogle Scholar
- Trey C, Davidson CS: The management of fulminant hepatic failure. Prog Liver Dis. 1970, 3: 282-298.PubMedGoogle Scholar
- Newsome PN, Plevris JN, Nelson LJ, Hayes PC: Animal models of fulminant hepatic failure: a critical evaluation. Liver Transpl. 2000, 6 (1): 21-31.PubMedGoogle Scholar
- Newsome PN, Bathgate AJ, Henderson NC, MacGilchrist AJ, Plevris JN, Masterton G, et al: Referral patterns and social deprivation in paracetamol-induced liver injury in Scotland. Lancet. 2001, 358 (9293): 1612-1613. 10.1016/S0140-6736(01)06663-6.View ArticlePubMedGoogle Scholar
- Gazzard BG, Hughes RD, Mellon PJ, Portmann B, Williams R: A dog model of fulminant hepatic failure produced by paracetamol administration. Br J Exp Pathol. 1975, 56 (5): 408-411.PubMedPubMed CentralGoogle Scholar
- Prescott LF, Roscoe P, Wright N, Brown SS: Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet. 1971, 1 (7698): 519-522. 10.1016/S0140-6736(71)91125-1.View ArticlePubMedGoogle Scholar
- Francavilla A, Makowka L, Polimeno L, Barone M, Demetris J, Prelich J, et al: A dog model for acetaminophen-induced fulminant hepatic failure. Gastroenterology. 1989, 96 (2 Pt 1): 470-478.PubMedPubMed CentralGoogle Scholar
- Kelly JH, Koussayer T, He DE, Chong MG, Shang TA, Whisennand HH, et al: An improved model of acetaminophen-induced fulminant hepatic failure in dogs. Hepatology. 1992, 15 (2): 329-335. 10.1002/hep.1840150225.View ArticlePubMedGoogle Scholar
- Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB: Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther. 1973, 187 (1): 195-202.PubMedGoogle Scholar
- Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB: Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther. 1973, 187 (1): 211-217.PubMedGoogle Scholar
- Griffith OW, Meister A: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979, 254 (16): 7558-7560.PubMedGoogle Scholar
- Miller DJ, Hickman R, Fratter R, Terblanche J, Saunders SJ: An animal model of fulminant hepatic failure: a feasibility study. Gastroenterology. 1976, 71 (1): 109-113.PubMedGoogle Scholar
- Schmid G, Neubauer G, Illievich UM, Alesch F: Dielectric properties of porcine brain tissue in the transition from life to death at frequencies from 800 to 1900 MHz. Bioelectromagnetics. 2003, 24 (6): 413-422. 10.1002/bem.10122.View ArticlePubMedGoogle Scholar
- Matsubara T, Koike M, Touchi A, Tochino Y, Sugeno K: Quantitative determination of cytochrome P-450 in rat liver homogenate. Anal Biochem. 1976, 75 (2): 596-603. 10.1016/0003-2697(76)90114-7.View ArticlePubMedGoogle Scholar
- Dacie JV, Lewis SM: Measurement of methaemoglobin in blood. Practical Haematology. Edited by: Dacie JV, Lewis SM. 1994, London: Churchill and LivingstoneGoogle Scholar
- Schmidt LE, Tofteng F, Strauss GI, Larsen FS: Effect of treatment with the Molecular Adsorbents Recirculating System on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy. Scand J Gastroenterol. 2004, 39 (10): 974-980. 10.1080/00365520410003227.View ArticlePubMedGoogle Scholar
- Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999, 29 (11): 1181-1189. 10.1080/004982599238047.View ArticlePubMedGoogle Scholar
- Terblanche J, Hickman R: Animal models of fulminant hepatic failure. Dig Dis Sci. 1991, 36 (6): 770-774. 10.1007/BF01311235.View ArticlePubMedGoogle Scholar
- Nelson LJ, Newsome PN, Howie AF, Hadoke PW, Dabos KJ, Walker SW, et al: An improved ex vivo method of primary porcine hepatocyte isolation for use in bioartificial liver systems. Eur J Gastroenterol Hepatol. 2000, 12 (8): 923-930. 10.1097/00042737-200012080-00012.View ArticlePubMedGoogle Scholar
- Baudouin SV, Howdle P, O'Grady JG, Webster NR: Acute lung injury in fulminant hepatic failure following paracetamol poisoning. Thorax. 1995, 50 (4): 399-402. 10.1136/thx.50.4.399.View ArticlePubMedPubMed CentralGoogle Scholar
- Bismuth H, Samuel D, Castaing D, Adam R, Saliba F, Johann M, et al: Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg. 1995, 222 (2): 109-119. 10.1097/00000658-199508000-00002.View ArticlePubMedPubMed CentralGoogle Scholar
- Blantz RC: Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis. 1996, 28 (1 Suppl 1): S3-S6. 10.1016/S0272-6386(96)90561-2.View ArticlePubMedGoogle Scholar
- Agar N, Board P: Red cell metabolism. Red blood cells of domestic animals. Edited by: Agar N, Board P. 1983, Amsterdam: Elsevier, 27-52.Google Scholar
- Henne-Bruns D, Artwohl J, Broelsch C, Kremer B: Acetaminophen-induced acute hepatic failure in pigs: controversical results to other animal models. Res Exp Med (Berl). 1988, 188 (6): 463-472. 10.1007/BF01852004.View ArticleGoogle Scholar
- Nash SL, Savides MC, Oehme FW, Johnson DE: The effect of acetaminophen on methemoglobin and blood glutathione parameters in the cat. Toxicology. 1984, 31 (3-4): 329-334. 10.1016/0300-483X(84)90114-8.View ArticlePubMedGoogle Scholar
- Savides MC, Oehme FW, Nash SL, Leipold HW: The toxicity and biotransformation of single doses of acetaminophen in dogs and cats. Toxicol Appl Pharmacol. 1984, 74 (1): 26-34. 10.1016/0041-008X(84)90266-7.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/10/34/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.